New pill combo aims to control advanced breast cancer
NCT ID NCT07557004
First seen May 06, 2026 · Last updated May 06, 2026
Summary
This early-stage study tests a new oral drug (SH3765) combined with fulvestrant in 30 women with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy. The main goals are to find a safe dose and check for side effects, while also measuring how well the combo shrinks or controls tumors. This is not a cure, but aims to better manage the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+, HER2-, ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital Of USTC Anhui Provincial Hospital
Hefei, Anhui, China
Conditions
Explore the condition pages connected to this study.